CSIMarket Company Name, Ticker, Industry, else..
 
Evelo Biosciences Inc   (NASDAQ: EVLO)
Other Ticker:  
 
 
Price: $0.0005 $0.00 0.000%
Day's High: $0.0005 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -66.67 %
Volume (M): 1 52 Wk High: $ 0.07
Volume (M$): $ 0 52 Wk Avg: $0.02
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 17
 Employees 30
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -52
 Capital Exp. (TTM) (Millions $) 0

Evelo Biosciences Inc
Evelo Biosciences Inc is a biotechnology company that specializes in developing and commercializing therapies for various diseases. The company focuses on the development of monoclonal microbials, which are oral therapies that modulate the activities of specific gut microbes to treat a range of diseases, including autoimmune, inflammatory, and metabolic diseases. Evelo Biosciences aims to harness the potential of the human gut-body network to discover and develop new treatments that can improve patient outcomes.


   Company Address: One Kendall Square, 600/700, Suite 7-201 Cambridge 2139 MA
   Company Phone Number: 577-0300   Stock Exchange / Ticker: NASDAQ EVLO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.24% 
BMY   -5.17%    
PFE   -1.76%    
REGN        6.47% 
TEVA   -3%    
VTRS   -2.81%    
• View Complete Report
   



Evelo Biosciences Inc

Evelo Biosciences Inc. Shatters Expectations with Remarkable Recovery; Operating Deficit Reduced to $-29.054 Million in Q3 2023



In the pharmaceutical industry, major players are closely scrutinizing the financial performance of Evelo Biosciences Inc during the third quarter of 2023. The company, having registered an operating deficit of $-11.183 million, demonstrated a significant improvement in cost-effectiveness compared to the same quarter in 2022. Additionally, there was a notable reduction in net losses, which is a crucial development for Evelo Biosciences Inc in the fiscal period ending September 30, 2023.
Operating Deficit:
Evelo Biosciences Inc revealed an operating deficit of $-11.183 million for the third quarter of 2023, showcasing an improvement from the $-29.054 million deficit in the corresponding quarter the previous year. Experts suggest that the small entity's ability to compete more cost-effectively contributed to this positive trend.
Evelo Biosciences Inc

Evelo Biosciences Inc Shows Encouraging Progress in Fiscal Period with Reduced Operating Deficit of $-19.574 Million



As the pharmaceutical industry continues to report their financial results for the April to June 2023 reporting cycle, Evelo Biosciences Inc, a leading company in the Major Pharmaceutical Preparations sector, has revealed its operating deficit. While the company still faces challenges in developing its business model, there are positive signs of progress as losses have been curbed compared to the previous year. This article aims to provide an overview of Evelo Biosciences' financial results, highlighting the improvements made in minimizing losses.
Financial Results:
Evelo Biosciences Inc recently announced an operating deficit of $-19.574 million for the most recent fiscal period. This signifies that the company's day-to-day operations have fared better in this period compared to the same period in the previous year. As Evelo Biosciences focuses primarily on research activities, it demonstrates its dedication to developing innovative solutions in the healthcare industry.
Evelo Biosciences Inc

Evelo Biosciences Inc Shows Promising Progress in Q1 2023 Financial Report, Significantly Reduces Operating Deficit

Evelo Biosciences Inc, a clinical stage biotechnology company that focuses on developing treatments for immune-mediated diseases and cancer, recently announced its operating deficit for the first quarter of 2023. The company reported a deficit of $-24.9 million which marked an improvement from the previous quarter?s operating deficit of $-28.738 million.
While the numbers may not represent a significant shift towards profitability, the improvement is still a positive sign for the company, especially given the volatile market landscape for the pharmaceutical industry. The reduction in the diminishing returns, which sat at $-25.341 million during the reported quarter, highlights Evelo Biosciences Inc?s commitment to running a more efficient and stable operation.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com